Malaria: Rwanda launches first African trial of a long-acting injection

One of the most anticipated trials in the fight against malaria is taking place in Rwanda. The organization Medicines for Malaria Venture (MMV) and its Rwandan partner Rinda Ubuzima have launched a phase 1b clinical trial for MMV371, an experimental drug administered as a single injection, Capital FM reported on November 6, 2026. According to the same source, this is the first phase 1 trial conducted in Africa for a long-acting injectable designed to prevent malaria.
The trial involves adults and adolescents. It aims to measure three things: the safety and tolerability of the product, how the body absorbs and eliminates it, and its potential effectiveness against infection. The number of participants and the specific sites selected were not disclosed.
An entire season, the hypothesis to be verified
The hope carried by this molecule is simple to state but difficult to achieve: an injection that provides protection for the duration of a transmission season. A previous trial conducted in the United Kingdom on healthy adults indicated protection lasting approximately three months. The product remains experimental and will need to pass further clinical stages before any widespread use: at this stage, nothing is guaranteed.
Martin Fitchet, CEO of MMV, believes that long-acting injectables have the "potential to redefine" how malaria prevention is delivered. For Marie Michele Umulisa, Executive Director of Rinda Ubuzima, conducting this study in Rwanda shows that such "partnerships" are essential, reports Capital FM.
Why the location matters as much as the product
Malaria caused more than 600,000 deaths worldwide in 2024, with over 280 million cases, according to World Health Organization figures cited in the article. Approximately 95% of these deaths occurred in Africa. The continent pays the highest price for this disease, yet it has long been the last to be served in the research chain: early trials were conducted elsewhere, results arrived later, and so did the prices.
The fact that a phase 1 trial is being held in Kigali this time, led by a Rwandan research team, shifts this dynamic. Safety data will be produced on the population that will be the first to be affected, and by researchers from the continent.
The next steps will depend on the results of this phase 1b, followed by larger-scale trials. But for families who, every rainy season, count the mosquito nets and the children's fevers, the stakes are concrete: knowing whether prevention might one day be achieved in a single visit to the clinic.
This article was written in French with the help of artificial intelligence from the sources cited below, then translated from French automatically. Read the original.

